Incyte Gets FDA Approval for Zynyz in New Cancer Indication

Incyte (INCY) announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, for treating a new cancer indication.The regulatory body has now approved Zynyz in combination with platinum-based chemotherapy (carboplatin and paclitaxel) for the first-line treatment of adult patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).Simultaneously, the FDA also approved Zynyz as a monotherapy for treating locally recurrent or metastatic SCAC in ...